ZBIO:NYE-Zenas BioPharma, Inc. (USD)

COMMON STOCK | Trading--Inverse Equity |

Last Closing

USD 18.53

Change

+1.49 (+8.74)%

Market Cap

N/A

Volume

0.25M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

N/A

USD 1.12B
SOXS Direxion Daily Semiconductor B..

-0.95 (-4.33%)

USD 0.85B
PSQ ProShares Short QQQ

-0.04 (-0.10%)

USD 0.58B
SPXU ProShares UltraPro Short S&P50..

-0.01 (-0.04%)

USD 0.54B
SDOW ProShares UltraPro Short Dow30

-0.04 (-0.30%)

USD 0.31B
DOG ProShares Short Dow30

-0.01 (-0.04%)

USD 0.16B
SPDN Direxion Daily S&P 500® Bear ..

-0.01 (-0.09%)

USD 0.16B
RWM ProShares Short Russell2000

+0.02 (+0.10%)

USD 0.15B
DUST Direxion Daily Gold Miners Ind..

+0.02 (+0.39%)

USD 0.12B
FNGD MicroSectors FANG+ Index -3X I..

-0.39 (-1.70%)

USD 0.11B

ETFs Containing ZBIO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 84.93% 100% F 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 84.93% 100% F 95% A
Trailing 5 Years  
Capital Gain 10.83% 100% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.83% 100% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain -0.13% N/A N/A 43% F
Dividend Return -0.12% N/A N/A 38% F
Total Return 0.00% N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 10.09% N/A N/A 88% B+
Risk Adjusted Return -1.23% N/A N/A 38% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike